Gardiquimod

Gardiquimod is an agonist of human toll-like receptor 7 (TLR7), but not human TLR8, although it activates both porcine TLR7 and TLR8. At 0.5 to 2 µg/ml, it enhances the immunosuppressive activity of T regulatory cells. Gardiquimod is effective as a mucosal adjuvant for Norwalk virus-like particles and inhibits infection of macrophages and T cells by HIV-1. It inhibits proliferation and migration while inducing apoptosis in pancreatic cancer cells in vitro.Formal Name: 4-amino-2-[(ethylamino)methyl]-alpha,alpha-dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol. CAS Number: 1020412-43-4. Molecular Formula: C17H23N5O. Formula Weight: 313.4. Purity: >95%. Formulation: (Request formulation change), A crystalline solid. Solubility: DMF: 20 mg/ml, DMSO: 20 mg/ml, Ethanol: 12 mg/ml, PBS (pH 7.2): 0.2 mg/ml. lambdamax: 249, 328 nm. SMILES: NC1=NC2=C(C3=C1N=C(CNCC)N3CC(C)(O)C)C=CC=C2. InChi Code: InChI=1S/C17H23N5O/c1-4-19-9-13-21-14-15(22(13)10-17(2,3)23)11-7-5-6-8-12(11)20-16(14)18/h5-8,19,23H,4,9-10H2,1-3H3,(H2,18,20). InChi Key: FHJATBIERQTCTN-UHFFFAOYSA-N.